Revvity, Inc. RVTY SPXR3KPHARMA

Healthcare · Diagnostics & Research · United States

https://www.revvity.com

Company Profile ↓

$130.22

+43.60% 1Y

Mkt Cap$14.53B

P/E62.61

P/B1.77

Div. Yield0.25%

52W High$130.94

52W Low$82.21

Book Value$64.76

EPS (TTM)$2.08

Company Overview

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Why Investors Should Care

Healthy Margins

Operating margin of 17.0% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $2.86B (+3.7% YoY); net profit $241.20M.
Trailing 12 Months Year-on-year growth — revenue +1.3%, earnings +1.1%.
5-Year Trend Long-term compounding — revenue CAGR 3.2%, profit CAGR 3.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	3.24%
1 Year:	1.30%

Compounded Profit Growth

5 Years:	3.87%
1 Year:	1.10%

Stock Price Performance

1 Year:	+43.60%
6 Months:	+42.77%
3 Months:	+32.46%
1 Month:	+13.99%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 99% of range

$82.21 $130.94

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)67.50 · Neutral

Price Performance

1M+13.99%

3M+32.46%

6M+42.77%

1Y+43.60%

Valuation vs Sector

P/E of 62.61 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 62.6.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

62.61

Industry PE

25.17

Forward P/E

22.10

PEG Ratio

0.71

Book Value

$64.76

Price to Book

1.77

P/S

4.39

EV/EBITDA

17.44

Dividend Yield

0.25%

Growth (CAGR)

Revenue 5Y

3.24%

Profit 5Y

3.87%

Revenue (YoY)

1.30%

Earnings (YoY)

1.10%

Profitability & Returns

ROCE

3.29%

ROE

3.21%

ROA

2.33%

Profit Margin

8.16%

Op Margin

17.03%

Gross Margin

54.98%

EPS (Latest Qtr)

$0.36

EPS (TTM)

$2.08

Balance Sheet & Liquidity

Debt/Equity

0.46

Quick Ratio

1.36

Current Ratio

1.80

Debt

$3.34B

Total Assets

$12.00B

Current Assets

Working Capital

Ownership

Promoter Holding

0.27%

Chg in Prom Hold

-0.09%

FII / Inst Holding

103.63%

Chg in FII Hold

0.03%

Financial Snapshot

Enterprise Value

$14.53B

Total Revenue (TTM)

$2.91B

EBITDA

$866.87M

Free Cash Flow

$599.39M

Operating Cash Flow

$627.63M

Shares Outstanding

111.56M

Gross Margin

54.98%

Payout Ratio

13.46%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	RVTY Revvity, Inc. SPXR3KPHARMA	130.22	62.61	$14.53B	0.25%	3.29%	3.21%	3.24%	3.87%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Oct 2015	Jan 2016	Apr 2016	Jul 2016	Oct 2016	Jan 2017	Apr 2017	Jul 2017	Oct 2017	Dec 2017	Apr 2018	Jul 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Apr 2020	Jul 2020	Oct 2020	Jan 2021	Apr 2021	Jul 2021	Oct 2021	Jan 2022	Apr 2022	Jul 2022	Oct 2022	Jan 2023	Apr 2023	Jul 2023	Oct 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Apr 2026
Revenue	-	-	-	-	-	-	-	546.96M	554.27M	-	643.97M	703.36M	674.31M	-	648.74M	722.52M	706.92M	-	652.40M	811.72M	964.02M	-	1.31B	1.23B	861.32M	-	963.16M	895.64M	711.80M	-	674.87M	709.07M	670.74M	649.92M	691.68M	684.05M	664.76M	720.28M	698.95M	711.12M
Gross Profit	239.37M	267.73M	235.09M	253.55M	248.55M	276.16M	239.76M	257.60M	268.97M	307.43M	292.22M	340.14M	332.33M	376.25M	307.81M	347.79M	342.27M	398.18M	308.02M	447.34M	527.45M	827.07M	693.19M	574.14M	522.86M	643.80M	594.74M	551.72M	407.04M	436.33M	-	-	-	-	-	-	-	-	-	-
Operating Income	67.39M	77.22M	60.58M	66.27M	75.78M	80.44M	49.81M	74.18M	78.04M	93.58M	39.94M	88.06M	80.20M	115.68M	53.33M	91.73M	78.66M	138.25M	44.68M	175.64M	248.01M	510.25M	455.01M	308.00M	195.55M	299.89M	261.96M	232.49M	110.78M	137.47M	76.12M	78.06M	69.23M	44.12M	85.72M	98.15M	72.23M	90.76M	81.90M	75.89M
Net Income	54.86M	68.25M	47.47M	63.86M	58.13M	64.85M	38.60M	204.07M	91.08M	-41.12M	26.02M	64.06M	76.55M	71.29M	35.41M	69.09M	58.56M	64.50M	33.66M	137.16M	176.70M	380.36M	379.31M	245.93M	127.74M	190.18M	176.96M	179.21M	85.35M	127.66M	569.48M	35.56M	9.50M	26.01M	55.36M	94.37M	42.24M	53.95M	46.65M	40.72M
Diluted EPS	0.48	0.61	0.43	0.58	0.53	0.59	0.35	1.84	0.82	-0.37	0.23	0.57	0.69	0.64	0.32	0.62	0.52	0.58	0.30	1.23	1.57	3.38	3.37	2.19	1.11	1.50	1.40	1.42	0.67	1.01	4.50	0.28	0.08	0.21	0.45	0.77	0.35	0.46	0.40	0.36
R&D Expense	31.09M	-	29.97M	31.87M	29.51M	-	33.29M	33.56M	34.88M	-	45.98M	47.20M	48.85M	-	47.98M	48.34M	45.38M	-	48.91M	49.52M	50.13M	-	60.22M	65.82M	49.42M	-	57.52M	56.04M	53.52M	-	56.69M	57.25M	53.04M	50.36M	48.13M	49.14M	53.60M	53.27M	50.80M	57.89M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Jan 2010	Jan 2011	Jan 2012	Dec 2012	Dec 2013	Dec 2014	Jan 2016	Jan 2017	Dec 2017	Dec 2018	Dec 2019	Jan 2021	Jan 2022	Jan 2023	Dec 2023	Dec 2024	Dec 2025
Revenue	1.66B	1.55B	1.70B	1.92B	2.12B	2.16B	2.24B	2.10B	2.12B	2.26B	2.78B	2.88B	2.66B	3.83B	3.31B	2.75B	2.76B	2.86B
Gross Profit	-	-	761.23M	847.80M	963.21M	976.14M	1.00B	964.23M	1.01B	1.07B	1.34B	1.40B	2.11B	2.43B	1.99B	-	-	-
Operating Income	147.63M	115.95M	157.57M	91.13M	103.12M	227.79M	165.01M	250.93M	294.58M	295.62M	323.88M	361.97M	867.27M	1.26B	742.70M	300.56M	346.74M	356.63M
Net Income	126.41M	82.08M	390.98M	7.66M	69.94M	167.21M	157.78M	212.43M	234.30M	292.63M	237.93M	227.56M	727.89M	943.16M	569.18M	693.09M	270.38M	241.20M
Diluted EPS	1.07	0.70	3.31	0.07	0.61	1.47	1.39	1.87	2.12	2.64	2.13	2.04	6.49	8.08	4.50	5.55	2.20	2.07
R&D Expense	93.03M	90.49M	94.81M	115.82M	131.84M	132.40M	108.06M	112.54M	124.18M	139.46M	194.00M	189.34M	146.44M	200.34M	221.62M	216.58M	196.84M	215.84M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Jan 2010	Jan 2011	Jan 2012	Dec 2012	Dec 2013	Dec 2014	Jan 2016	Jan 2017	Dec 2017	Dec 2018	Dec 2019	Jan 2021	Jan 2022	Jan 2023	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	3.06B	3.21B	3.86B	3.90B	3.95B	4.13B	4.17B	4.28B	6.09B	5.98B	6.54B	7.96B	15.00B	14.13B	13.56B	12.39B	12.17B
Total Equity	1.58B	1.57B	1.63B	1.93B	1.84B	1.94B	1.99B	2.04B	2.11B	2.15B	2.50B	2.58B	2.81B	3.74B	7.14B	7.38B	7.87B	7.67B	7.25B
Cash & Equivalents	203.35M	179.11M	179.71M	420.09M	142.34M	173.24M	174.82M	174.82M	237.93M	359.26M	202.13M	163.11M	191.88M	387.05M	603.32M	454.36M	913.16M	1.16B	919.86M
Long Term Debt	-	-	558.20M	424.00M	944.91M	938.82M	932.10M	1.05B	1.01B	1.05B	1.79B	1.88B	2.06B	1.61B	4.98B	3.92B	3.18B	3.15B	2.63B
Total Liabilities	-	-	1.43B	1.28B	2.01B	1.96B	1.95B	2.09B	2.06B	2.12B	3.59B	3.39B	3.72B	4.22B	7.86B	6.75B	5.69B	4.73B	4.92B
Current Liabilities	-	-	497.20M	515.20M	598.68M	581.10M	602.80M	597.31M	561.49M	603.36M	950.90M	771.63M	762.83M	1.65B	1.21B	1.54B	1.45B	653.10M	1.33B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2008	Jan 2010	Jan 2011	Jan 2012	Dec 2012	Dec 2013	Dec 2014	Jan 2016	Jan 2017	Dec 2017	Dec 2018	Dec 2019	Jan 2021	Jan 2022	Jan 2023	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	217.84M	148.72M	164.25M	224.87M	152.17M	158.59M	281.60M	287.10M	350.62M	288.45M	311.04M	363.47M	892.18M	1.41B	679.81M	91.27M	628.30M	582.93M
Investing Cash Flow	-135.68M	-153.87M	295.15M	-909.86M	-80.31M	-1.21M	-295.90M	-100.86M	-83.88M	-1.27B	-159.86M	-487.57M	-504.50M	-4.11B	-132.85M	1.31B	776.16M	-17.35M
Financing Cash Flow	-101.08M	2.41M	-218.37M	397.20M	-44.16M	-154.16M	30.93M	-107.14M	-115.01M	782.24M	-179.23M	-150.13M	-202.87M	2.94B	-661.80M	-947.12M	-1.13B	-857.52M
Capital Expenditure	-35.27M	-25.52M	-33.65M	-30.59M	-42.40M	-38.98M	-27.15M	-28.22M	-31.70M	-39.09M	-93.25M	-76.33M	-63.63M	-86.02M	-85.63M	-81.37M	-86.65M	-73.52M
Free Cash Flow	182.57M	123.21M	130.61M	194.28M	109.77M	119.61M	254.44M	258.88M	318.91M	249.36M	217.78M	287.14M	828.54M	1.32B	594.18M	9.90M	541.65M	509.41M
Share Buybacks	75.51M	14.62M	72.77M	110.00M	2.10M	127.40M	65.53M	76.44M	151.80M	3.83M	57.45M	6.31M	6.94M	73.07M	80.64M	388.88M	369.58M	820.82M

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Jan 2010	Jan 2011	Jan 2012	Dec 2012	Dec 2013	Dec 2014	Jan 2016	Jan 2017	Dec 2017	Dec 2018	Dec 2019	Jan 2021	Jan 2022	Jan 2023	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	44.7%	44.2%	45.5%	45.2%	44.9%	45.8%	47.9%	47.6%	48.3%	48.4%	79.2%	63.6%	60.1%	-	-	-
Operating Margin %	8.9%	7.5%	9.2%	4.7%	4.9%	10.6%	7.4%	11.9%	13.9%	13.1%	11.7%	12.6%	32.6%	32.9%	22.4%	10.9%	12.6%	12.5%
Net Margin %	7.6%	5.3%	22.9%	0.4%	3.3%	7.7%	7.1%	10.1%	11.1%	13.0%	8.6%	7.9%	27.3%	24.6%	17.2%	25.2%	9.8%	8.4%
ROE %	8.1%	5.0%	20.3%	0.4%	3.6%	8.4%	7.7%	10.1%	10.9%	11.7%	9.2%	8.1%	19.5%	13.2%	7.7%	8.8%	3.5%	3.3%
ROCE %	-	4.5%	5.8%	2.8%	3.1%	6.8%	4.7%	7.0%	8.0%	5.8%	6.2%	6.3%	13.7%	9.1%	5.9%	2.5%	3.0%	3.3%

Shareholding Pattern

Insiders

0.27%

Institutions

103.63%

Public Float

103.91%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	T. Rowe Price Investment Management, Inc.	16.37%	18.26M	$2.35B
2	Jupiter Topco LLC	7.74%	8.64M	$1.11B
3	Edgepoint Investment Group Inc.	7.66%	8.54M	$1.10B
4	Blackrock Inc.	6.86%	7.66M	$986.40M
5	Vanguard Capital Management LLC	6.54%	7.30M	$940.37M
6	Price (T.Rowe) Associates Inc	4.96%	5.53M	$712.37M
7	Vanguard Portfolio Management LLC	4.28%	4.77M	$614.43M
8	State Street Corporation	3.89%	4.34M	$559.34M
9	Victory Capital Management Inc.	3.27%	3.65M	$469.59M
10	Dimensional Fund Advisors LP	3.07%	3.43M	$441.62M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RVTY

Yahoo Finance Fri, 04 Sep 2026

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.

Yahoo Finance hu, 03 Sep 2026

Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings

Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multi…

Yahoo Finance Wed, 02 Sep 2026

Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade

Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price …

Yahoo Finance ue, 01 Sep 2026

3 Hyped Up Stocks We Find Risky

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.…

Yahoo Finance ue, 01 Sep 2026

What Makes Revvity (RVTY) a New Buy Stock

Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo Finance ue, 01 Sep 2026

Revvity Faces Growth Challenges Amid Rising Competition, RBC Says

Revvity's (RVTY) strong portfolio faces slowing growth and rising competition, raising questions abo

RVTY — Frequently Asked Questions

What is the current share price of Revvity, Inc. (RVTY)?

As of 2026-09-07 16:24 PDT, Revvity, Inc. (RVTY) trades at $130.22 on NYSE. Its 52-week range is $82.21 to $130.94.

What is the market capitalisation of RVTY?

Revvity, Inc. (RVTY) has a market capitalisation of $14.53B on NYSE.

What is the P/E ratio of RVTY?

RVTY trades at a trailing price-to-earnings (P/E) ratio of 62.61. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.77.

Does RVTY pay a dividend?

Revvity, Inc. (RVTY) currently offers a dividend yield of 0.25%.

What is the return on equity (ROE) of RVTY?

RVTY has a return on equity (ROE) of 3.21%. Its return on capital employed (ROCE) is 3.29%.

Is RVTY a good stock to buy?

This page provides a data-driven analysis of Revvity, Inc. (RVTY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Revvity, Inc. RVTY SPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings

Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade

3 Hyped Up Stocks We Find Risky

What Makes Revvity (RVTY) a New Buy Stock

Revvity Faces Growth Challenges Amid Rising Competition, RBC Says

RVTY — Frequently Asked Questions

What is the current share price of Revvity, Inc. (RVTY)?

What is the market capitalisation of RVTY?

What is the P/E ratio of RVTY?

Does RVTY pay a dividend?

What is the return on equity (ROE) of RVTY?

Is RVTY a good stock to buy?

Explore More